Smart Meter Remote Patient Monitoring Powered by AT&T IoT Connectivity

What Is It? Helps Improve Outcomes for Patients with Chronic Conditions

AT&T* is teaming up with Smart Meter to improve health outcomes for patients with chronic conditions like diabetes and high blood pressure. Smart Meter supplies healthcare providers with cellular remote patient monitoring (RPM) devices and services, including the SmartRPM™ solution, iGlucose®, iBloodPressure 2.0™, iScale™ and soon, the iPulseOx™, being unveiled at CES 2022 in Las Vegas. These devices run on AT&T’s nationwide IoT network, known for its reliability and coverage.

Chronic diseases are the leading causes of death in the U.S., and they’re on the rise. Hypertension can lead to 2 of the biggest killers in this country – heart disease and stroke – while diabetes ranks 7th for deaths. But studies show remote patient monitoring can help change this. For example, 84% of diabetes and 88%1 of hypertension patients at highest risk for severe disease complications experienced significant improvements in their health when using the Smart Meter iGlucose and iBloodPressure as part of RPM programs.

Why is this important? Consistent use is a must for an effective RPM program. So, the simpler the solution, the more likely the patient will use it. Smart Meter’s cellular-enabled devices simplify RPM. They are an easy out-of-the-box solution; just insert the included batteries and press the start button. The monitoring devices contain IoT SIM cards, so they automatically send the patient’s data over the AT&T IoT network to the SmartRPM cloud. The healthcare provider then accesses the data there via secure log-in.

Unlike cellular-enabled RPM devices, Bluetooth-enabled monitoring devices require the user to pair the device with a smartphone or tablet, download the data, and then send it to the doctor. It’s a more complicated solution that oftentimes involves troubleshooting. This can be intimidating and frustrating for users and can lead to them not continuing with the RPM program. Cellular RPM devices help lessen the technological divide and are more accessible to patients of all ages, regardless of digital literacy and access to connectivity.

What are the benefits?

For patients, Smart Meter’s cellular RPM devices mean easy access to improved healthcare with the peace of mind that comes from frequent assurances and support. For health care providers, the benefits include ready access to more complete patient data and the ability to act on it in near real-time, while automatic record-keeping meets requirements for reimbursement.

Because of these benefits, a growing number of doctors are embracing RPM. A recent survey found 43% of clinicians believe RPM adoption will be on par with in-patient monitoring in 5 years.

What are people saying?

“The iGlucose solution proved to be an outstanding resource for my clinical team to enable greater insights into our patients’ results between visits. More than 70% of participants required some form of intervention prior to their next in-office visit, and as a result, there was a reduction in emergency room visits and need for hospitalizations, demonstrating better overall diabetes care.” – Dr. Gail L. Nunlee-Bland, MD, Howard University Diabetes Treatment Center.

“Our collaboration with Smart Meter is another example of how our IoT connectivity is advancing connected healthcare. IoT-enabled devices ultimately provide a quicker and more convenient patient service with better outcomes for both the patient and the healthcare provider.” – Joe Drygas, VP of AT&T Healthcare Industry Solutions.

“As an early RPM innovator, Smart Meter has done extensive work to drive the best outcomes by improving patient engagement and adherence, and our cellular alliance with AT&T has been a large part of our success.” – Casey Pittock, Smart Meter CEO.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy